An Open-label Single Center Study to Evaluate the Efficacy of SILIQ™ (Brodalumab) for the Treatment of Moderate Hidradenitis Suppurativa
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Brodalumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
Most Recent Events
- 05 Apr 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Apr 2019 )
- 12 Apr 2019 New trial record